Theriva Biologics Inc. (TOVX)
AMEX: TOVX
· Real-Time Price · USD
0.49
-0.02 (-3.54%)
At close: Jul 24, 2025, 3:59 PM
Theriva Biologics Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | n/a | 154K | n/a | n/a | n/a | 758K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | n/a | 77K | 33K | 38K | 39K | 39K | 134K | 131K | 114K | 25K | 24K | 18K | 18K | 13K | 18K | 23K | 33K |
Gross Profit | n/a | 77K | n/a | -38K | -39K | 719K | -134K | -131K | -114K | -25K | -24K | -18K | -18K | -13K | -18K | -23K | -33K |
Operating Income | -4.42M | -4.58M | -7.89M | -8.49M | -5.39M | -5.88M | -4.22M | -5.82M | -5.18M | -7.33M | -5.01M | -4.99M | -4.25M | -5.26M | -3.27M | -3.2M | -2.54M |
Interest Income | 96K | 138K | 158K | 173K | 228K | 312K | 382K | 381K | 364K | 315K | 170K | 26K | 2K | 2K | 2K | 2K | n/a |
Pretax Income | -4.32M | -4.45M | -7.73M | -8.32M | -5.17M | -5.91M | -3.83M | -5.44M | -4.81M | -7.02M | -4.85M | -4.97M | -4.27M | -5.26M | -3.27M | -3.19M | -2.54M |
Net Income | -4.32M | -4.45M | -7.73M | -8.32M | -5.17M | -5.49M | -3.3M | -5.08M | -4.48M | -5.59M | -4.7M | -4.96M | -4.32M | -5.26M | -3.27M | -3.19M | -2.54M |
Selling & General & Admin | 1.45M | 1.73M | 2.3M | 1.47M | 1.89M | 1.64M | 212K | 2.69M | 2.2M | 4.26M | 2.44M | 1.5M | 1.66M | 2.49M | 1.3M | 1.26M | 1.42M |
Research & Development | 2.97M | 2.89M | 2.73M | 2.95M | 3.46M | 4.2M | 4.01M | 3.13M | 2.98M | 3.07M | 2.57M | 3.48M | 2.6M | 2.78M | 1.97M | 1.93M | 1.12M |
Other Expenses | n/a | n/a | 2.85M | 4.07M | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 4.42M | 4.58M | 5M | 4.38M | 5.35M | 5.84M | 4.22M | 5.82M | 5.18M | 7.33M | 5.01M | 4.99M | 4.25M | 5.26M | 3.27M | 3.2M | 2.54M |
Interest Expense | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | 39K | n/a | n/a | -39K | -378K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 4.42M | 4.7M | 7.89M | 8.49M | 5.39M | 5.88M | 4.22M | 5.82M | 5.18M | 7.33M | 5.01M | 4.99M | 4.25M | 5.26M | 3.27M | 3.2M | 2.54M |
Income Tax Expense | n/a | 1K | n/a | n/a | -4.28K | -424K | -527K | -359K | -330K | -1.74M | -152K | -8K | 44K | -13K | n/a | n/a | -1K |
Shares Outstanding (Basic) | 2.78M | 1.35M | 1.13M | 775K | 685.9K | 685.92K | 681.71K | 606.65K | 604.96K | 629.19K | 15.84M | 15.84M | 13.82M | 13.2M | 13.2M | 13.2M | 9.08M |
Shares Outstanding (Diluted) | 2.78M | 1.35M | 1.13M | 775.74K | 685.9K | 685.92K | 681.71K | 606.65K | 604.96K | 629.19K | 15.84M | 15.84M | 13.82M | 13.2M | 13.2M | 13.2M | 9.08M |
EPS (Basic) | -1.55 | 15.73 | -6.81 | -10.75 | -7.53 | -8 | -4.85 | -8.38 | -7.4 | -8.89 | -0.3 | -0.31 | -0.31 | -0.4 | -0.25 | -0.24 | -0.28 |
EPS (Diluted) | -1.55 | 15.73 | -6.81 | -10.72 | -7.53 | -8 | -4.85 | -8.38 | -7.4 | -8.89 | -0.3 | -0.31 | -0.31 | -0.4 | -0.25 | -0.24 | -0.28 |
EBITDA | -4.42M | -4.55M | -5M | -4.38M | -5.35M | -5.87M | -4.22M | -5.82M | -5.15M | -6.99M | -4.96M | -5.01M | -4.23M | -5.25M | -3.26M | -3.17M | -2.5M |
EBIT | n/a | -4.45M | -5.04M | -4.42M | -5.39M | -6.22M | -3.83M | -5.82M | -5.18M | -7.33M | -4.99M | -5.03M | -4.25M | -5.26M | -3.27M | -3.2M | -2.54M |
Depreciation & Amortization | n/a | 27K | 33K | 38K | 39K | 39K | 134K | 131K | 114K | 25K | 24K | 18K | 18K | 13K | 18K | 23K | 33K |